Modulite®: A Simple Solution to a Difficult Problem
- 1 May 2005
- journal article
- research article
- Published by S. Karger AG in Respiration
- Vol. 72 (Suppl. 1), 3-5
- https://doi.org/10.1159/000083686
Abstract
The development of HFA-based pMDIs has proved difficult due to differences in the physico-chemical properties of CFC and HFA propellants. However, the development of solution formulations instead of suspensions has provided a way to formulate products whose cloud characteristics can be modulated in a controlled manner by permitting different formulation and device hardware variables. The new approach has proved successful in formulating several different drugs including steroids and has now been applied to developing a formoterol Modulite solution formulation characterized by good chemical stability, delivery performance, and clinical results.Keywords
This publication has 5 references indexed in Scilit:
- Efficacy and safety of inhaled budesonide delivered once or twice daily via HFA-134a in mild to moderate persistent asthma in adult patients. Comparison with budesonide CFCRespiratory Medicine, 2003
- Clinical studies in asthmatics with a new non-extra fine HFA formulation of beclometasone dipropionate (BDP Modulite®)Respiratory Medicine, 2002
- Modulite®: a means of designing the aerosols generated by pressurized metered dose inhalersRespiratory Medicine, 2002
- Transition to CFC-free metered dose inhalers — into the new millenniumInternational Journal of Pharmaceutics, 2000
- Drug–surfactant–propellant interactions in HFA-formulationsInternational Journal of Pharmaceutics, 1999